References

1. Science and engineering indicators. National Science Board View
2. EPA Enforcement & Compliance History Online (ECHO). View
3. DEC Data Report (2004). View
4. Throssel OW/ORD Emerging Contaminants Workgroup (2008) Aquatic Life Criteria for Contaminants of Emerging Concern: Challenges and Recommendations. EPA. View
5. Cleuvers M (2004) Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. Ecotoxicol Environ Saf 59: 309-315.
6. Caldwell DJ, Mastrocco F, Hutchinson TH, Lange R, Heijerick D, et al. (2008) Derivation of an aquatic predicted no-effect concentration for the synthetic hormone, 17 alpha-ethinyl estradiol. Environ Sci Technol 42: 7046-7054. View
7. EPA (2012) Pharmaceuticals and Personal Care Products as Pollutants (PPCPs). EPA. U.S. Environmental protection Agency Internet]. View
8. Snyder S, Lei H, Wert E, Westerhoff P, Yoon Y (2008) Removal of EDCs and Pharmaceuticals in Drinking Water. Water Environment Research Foundation. View
9. Barnes KK, Kolpin DW, Meyer MT, Thurman EM, Furlong ET, et al. (2002) Water-quality data for pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: U.S. Geological Survey Open-File Report 02-94. U.S. Geological Survey [Internet]. View
10. Kuster M, de Alda MJL, Hernando MD, Petrovic M, Martín-Alonso J, et al. (2008) Analysis and occurrence of pharmaceuticals, estrogens, progestogens and polar pesticides in sewage treatment plant effluents, river water and drinking water in the Llobregat river basin (Barcelona, Spain). Journal of Hydrology 358: 112-123. View
11. Cheri G (2009) Statement of Cheri, Garvin on behalf of the national community pharmacists association submitted to united states house of representatives committee on the judiciary subcommittee on crime, terrorism, and homeland security at a hearing on secure and responsible drug disposal. [Internet]. View
12. Hernando MD, Mezcua M, Fernández-Alba AR, Barceló D (2006) Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta, 69: 334-342. View
13. Hannah R, D'Aco VJ, Anderson PD, Buzby ME, Caldwell DJ, et al. (2009) Exposure assessment of 17α-ethinylestradiol in surface waters of the United States and Europe. Environmental Toxicology and Chemistry 28: 2725-2732. View
14. Länge R, Hutchinson TH, Croudace CP, Siegmund F, Schweinfurth H, et al. (2001) Effects of the synthetic estrogen 17α-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas). Environmental Toxicology and Chemistry 20: 1216-1227. View
15. Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, et al. (2007) Collapse of a fish population after exposure to a synthetic estrogen. Proceedings of the National Academy of Sciences 104: 8897-8901. View
16. Caldwell DJ, Mastrocco F, Hutchinson TH, Länge R, Heijerick D, et al. (2008) Derivation of an aquatic predicted no-effect concentration for the synthetic hormone, 17α-ethinyl estradiol. Environmental science & technology 42: 7046-7054. View
17. Kümmerer K (2010) Pharmaceuticals in the Environment. The Annual Review of Environment and Resources [Internet] 35: 57-75. View
18. Webb JS, S McGinness, Lappin-Scott HM (1998) Metal removal by sulphate-reducing bacteria from natural and constructed wetlands. J Appl Microbiol 84: 240-248. View
19. Gopal B (1999) Natural and constructed wetlands for wastewater treatment: Potentials and problems. Water Sci Technol 40:27-35. View
20. Hijosa-Valsero M, Fink G, Schlusener MP, Sidrach-Cardona R, Martin- Willacorta J, et al. (2011) Removal of antibiotics form urban wastewater by constructed wetland optimization. Chemosphere 83: 713-719. View
21. Matamoros V, Bayona JM (2006) Elimination of Pharmaceutical and Personal Care Products in Subsurface Flow Constructed Wetlands. Environ Sci Technol 40: 5811-5816. View
22. Hijosa-Valsero M, Sidrach-Cardona R, Becares E (2012) Comparison of interannual removal variation ofvarious constructed wetland types. Science of the Total Environment 430: 174-183. View
23. Matamoros V, Hijosa M, Bayona JM (2009) Assessment of the pharmaceutical active compounds removalin wastewater treatment systems at enantiomeric level. Ibuprofen and naproxen. Chemosphere 75: 200-205. View
24. U.S. EPA (1993) Constructed Wetlands for Wastewater Treatment and Wildlife Habitat: 17 Case Studies. View
25. National Center for Biotechnology Information (2017) PubChem Database. View
26. U.S. Environmental Protection Agency (EPA): Office of Water, Office of Science and Technology, View
27. Engineering and Analysis Division (4303T) December 2007. EPA Method 1694: Pharmaceuticals andPersonal Care Products in Water, Soil, Sediment, and Biosolids by HPLC/MS/MS. Reference numberEPA- 821-R-08-002. View
28. Maciolek DJ, Austin DC (2006) Low energy biological nitrogen removal by cation exchange, thin filmoxygen transfer, and heterotrophic nitrification in sequencing-batch, packed-bed reactors. WEFTEC Water Environment Federation 21-26: 1560-1582.
29. Reddy KR, D’Angelo EM (1997) Biogeochemical indicators to evaluate pollutant removal efficiency inconstructed wetlands. Water Science and Technology 35:1-10. View
30. Kadlec RH, Wallace SD (2009) Treatment Wetlands 2nd ed. Taylor & Francis Group, LLC. CRC Press.
31. Vymazal J (2005) Horizontal sub-surface flow and hybrid constructed wetlands systems for wastewater treatment. Ecological Engineering 5: 478-490.
32. Image by Klaus Dölle, Basic layout of a S2BR cell, pdf-file.
33. Image by Klaus Dölle, Layout of waste water treatment plant with sample points before rebuild, pdf-file.
34. Image by Klaus Dölle, Layout of waste water treatment plant with sample points after rebuild, pdf-file.